This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Phase 3, Randomized, Double-Blind, Placebo-Contr...
Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Read time: 1 mins
Last updated:29th Apr 2013
To evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)
Category Value
Study start date 2013-04-29

View full details